ZNTL250117C10000
- 0.15
- 0.000.00%
Zentalis Pharmaceuticals Newsroom
Guggenheim Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Cuts Target Price to $8
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $8 to $20
HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $20 Price Target
Zentalis Pharma Analyst Ratings
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $8 to $9
Cautious Hold on Zentalis Pharmaceuticals Amid Strategic Shifts and Safety Concerns
Zentalis Pharmaceuticals: Strong Leadership and Promising Clinical Developments Justify Buy Rating
Stifel Nicolaus Remains a Buy on Zentalis Pharmaceuticals (ZNTL)
Stifel Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9
Stifel Nicolaus Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)
Morgan Stanley Downgrades Zentalis Pharmaceuticals(ZNTL.US) to Hold Rating, Cuts Target Price to $8
Maintaining Hold on Zentalis Pharmaceuticals Amidst Positive Regulatory Developments and Upcoming Clinical Milestones
TD Cowen Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating
Zentalis Pharma Analyst Ratings
Oppenheimer Reiterates Outperform on Zentalis Pharma, Maintains $20 Price Target
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $20
Zentalis Pharmaceuticals Price Target Announced at $4.00/Share by Wedbush
Wells Fargo Sticks to Their Hold Rating for Zentalis Pharmaceuticals (ZNTL)
Zentalis Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $20 Price Target